An ACE inhibitor indicated for the treatment of hypertension, acute myocardial infarction, and adjunct therapy for heart failure, this drug received its first generic approval

A GLP-1 receptor agonist, this drug was previously approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, this drug has now been approved to reduce the risk of major adverse cardiovascular (CV) events – including CV death, non-fatal myocardial infarction, and non-fatal stroke – in patients with type 2 diabetes who are at high risk for these events

Indicated for the treatment of hypertension, to lower blood pressure in adults.

Indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH).

Indicated for the treatment of hypertension to lower blood pressure, a new oral solution formulation of this drug is now available

Indicated for the treatment of hypertension to lower blood pressure, in patients 55 and older to reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes, and in patients with post-myocardial infarction heart failure to reduce risk of death and hospitalization

Indicated alone or in combination with other antihypertensive and antianginal agents for the treatment of hypertension or coronary artery disease

Indicated to reduce the risk of stroke, major cardiovascular events in patients with coronary artery disease, and for the treatment of several other cardiovascular concerns. In March, a 2.5 mg dose of this generic was approved; this approval applies to 10 mg, 15 mg, and 20 mg doses

Indicated to reduce the risk of stroke, major cardiovascular events in patients with coronary artery disease, and for the treatment of several other cardiovascular concerns

Indicated for the treatment of pulmonary arterial hypertension, this is the first and only dry-powder formulation of treprostinil

Indicated for the treatment of hypertension, stroke risk reduction in patients with hypertension and left ventricular hypertrophy, and diabetic neuropathy in certain type 2 diabetes patients with hypertension

Indicated for the treatment of hypertension alone or with other antihypertensive agents, and for the treatment of enlarged prostate

Indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure

A first-in-class biologic indicated for the treatment of pulmonary arterial hypertension to increase exercise capacity and reduce the risk of clinical worsening events

Indicated for the treatment of pulmonary arterial hypertension, both in patients who are treatment naïve or who are already on an ERA, PDE5 inhibitor or both